Celebrating the “State of Possible” – CCC to Attend MassBio’s Annual Conference
As new members of the Massachusetts Biotechnology Council, the CCC team is excited to join this year’s event entitled “The State of Possible.”
Supercharging Search: AI in Information Discovery for the Life Sciences [Upcoming Webinar]
CCC and SciBite’s complimentary webinar will focus on a method to cut through the complexity of scientific language to retrieve better search results.
Information Overload? Not Necessarily the Case for Emerging Life Science Companies
Are researchers in emerging life science companies suffering from ‘information underload’? CCC’s Jill Shuman reached out to scientific researchers to find out the answer.
2018 in Review: CCC’s Top Headlines on Digital Transformation, Copyright Law and Open Access
Notable topics from 2018 included digital transformation, info management in life sciences, Open Access and copyright legislation.
How Agile Are You? Why R&D Strategy, Structure & Decision Making Needs to Shift
As pharma companies look to improve their R&D productivity in the new year, some are shifting from a traditional mindset… Read more
What the World’s Largest IT Leadership Study Tells Us About the State of the Pharma Industry
The latest Harvey Nash/KPMG CIO Survey – the largest IT leadership study in the world – helps us gauge how pharma firms are adopting digital technologies.
Big Pharma Launches Digital Transformation Plans into Overdrive
Pharma industry leaders are realizing the impact of digital transformation efforts. But new research shows 3 in 4 are still in the early phases of digital development.
Attending the European Continuing Medical Education (CME) Forum? Here Are 5 Session Picks
Stakeholders with an interest in European Continuing Medical Education (CME), will meet next week for the 11th Annual European CME Forum.
AI Usage Growing Among Life Sciences Professionals – But Challenges Remain
From entertainment to healthcare, ecommerce to finance – it’s undeniable that the way we do business changes when artificial intelligence… Read more
FDA’s Office of New Drugs Wants in on the Big Data Revolution
The FDA’s Office of New Drugs is being “bombarded” by data and decision-making is suffering as a result. They aren’t alone in this challenge.